Linkedin
RLS logo_header
Linkedin

KeyVibe and KEYFORM Clinical Programs of Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab to be discontinued

“Following a careful analysis of the data, the decision has been made to discontinue development of these candidates to prioritize other ongoing programs. We are grateful to all the patients, caregivers and investigators for their many contributions that made these studies possible,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “We continue to pursue the most promising science with a focus on agents with the greatest potential to improve outcomes for more patients with cancer.”

Read the full story on "KeyVibe and KEYFORM Clinical Programs of Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab to be discontinued"

Share:

More News

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

“This acquisition further strengthens our late-stage oncology pipeline and reflects our continued focus on bringing transformational treatments to people living with cancer,” said David Loew, CEO, Ipsen. “We are excited by the potential of navtemadlin to define a new treatment paradigm for patients with myelofibrosis who have a suboptimal response

Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors

“We are pleased to partner with Roche to explore the combination potential of EXP011 and atezolizumab for patients with SCLC and other hard-to-treat solid tumors.” said Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics. “This collaboration enables us to evaluate a differentiated immuno-oncology combination strategy to address

Positive Ph 3 Results for BRUKINSA in Frontline MCL Announced

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally. We believe

Novartis to acquire Myricx Bio for ADCs with N-myristoyltransferase inhibitor (NMTi) payloads

“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, President of Biomedical Research at Novartis. “Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism